Prevalence, Incidence, Clinical Presentation, and Treatment of Polyendocrine Metabolic Ovarian Syndrome in Primary Care in the United Kingdom Between 1998 and 2025
Clinical Endocrinology · 11.11.2026
DOI: 10.1111/cen.70231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 11.11.2026. Verfasst von Samantha B Shapiro und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Objective
Polyendocrine metabolic ovarian syndrome (PMOS) is a multisystemic disorder with a wide range of health consequences. We sought to describe temporal trends in the prevalence and incidence of PMOS and to characterize its clinical presentation, comorbidity burden, and pharmacological management in primary care in the United Kingdom (UK) between 1998 and 2025.
Design
Population‐based matched cohort study using primary care records from the UK Clinical Practice Research Datalink. Patients Females newly diagnosed with PMOS between the ages of 15 and 49 matched on age, general practice, calendar year of cohort entry, and duration of medical history to population controls without PMOS.
Measurements
Annual prevalence and incidence of diagnosed PMOS; baseline prevalence and incidence of cardinal PMOS features and various comorbidities; and pre‐ and post‐cohort entry prevalence of hormonal contraceptive, anti‐androgen, ovulation‐inducing drug, and metformin use.
Results
The prevalence of diagnosed PMOS increased from < 0.1% in 1998 to 2.0% in 2025, with incidence rising from 0.1 to 3.6 per 1,000 person‐years over the same period. Among 125,482 patients with newly diagnosed PMOS matched with an equal number of controls, patients with PMOS had higher baseline prevalence and incidence of cardinal features of PMOS, as well as diabetes, dyslipidemia, hypertension, cardiovascular and cerebrovascular disease, sleep apnea, thyroid disorders, endometriosis, uterine fibroids, chronic pain, depression, and anxiety. Use of anti‐androgens, ovulation‐inducing drugs, and metformin was substantially higher in patients with PMOS, especially in the year following diagnosis.
Conclusions
PMOS is increasingly diagnosed in UK primary care and is associated with substantial multimorbidity and pharmacotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
- Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.
- Division of Endocrinology, Jewish General Hospital, Montreal, Quebec, Canada.
- Department of Obstetrics and Gynecology, McGill University Medical Center, Montreal, Quebec, Canada.
- Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Samantha B Shapiro, Oriana H Y Yu, Michael H Dahan, Laurent Azoulay
Zitieren
APA
Shapiro, S. B., Yu, O. H. Y., Dahan, M. H., & Azoulay, L. (2026). Prevalence, Incidence, Clinical Presentation, and Treatment of Polyendocrine Metabolic Ovarian Syndrome in Primary Care in the United Kingdom Between 1998 and 2025. Clinical Endocrinology. https://doi.org/10.1111/cen.70231
Vancouver
Shapiro SB, Yu OHY, Dahan MH, Azoulay L. Prevalence, Incidence, Clinical Presentation, and Treatment of Polyendocrine Metabolic Ovarian Syndrome in Primary Care in the United Kingdom Between 1998 and 2025. Clinical Endocrinology. 2026. doi:10.1111/cen.70231
BibTeX
@article{Shapiro2026,
author = {Shapiro, Samantha B and Yu, Oriana H Y and Dahan, Michael H and Azoulay, Laurent},
title = {Prevalence, Incidence, Clinical Presentation, and Treatment of Polyendocrine Metabolic Ovarian Syndrome in Primary Care in the United Kingdom Between 1998 and 2025},
journal = {Clinical Endocrinology},
year = {2026},
doi = {10.1111/cen.70231}
}
EUVIMED